Ulblock^® (Capsules) Instructions for Use

ATC Code

A02BC04 (Rabeprazole)

Active Substance

Rabeprazole (Rec.INN WHO registered)

Clinical-Pharmacological Group

H⁺-K⁺-ATPase inhibitor. Antiulcer drug

Pharmacotherapeutic Group

Acid-related disorder treatment agents; antiulcer agents for the treatment of gastroesophageal reflux disease (GERD); proton pump inhibitors

Pharmacological Action

Proton pump inhibitor. Rabeprazole belongs to the class of antisecretory compounds that are chemically substituted benzimidazoles.

Rabeprazole inhibits the activity of the H+/K+ ATPase enzyme (proton pump), thereby blocking the final stage of hydrochloric acid synthesis.

This effect is dose-dependent and leads to the inhibition of both basal and stimulated secretion of hydrochloric acid, regardless of the stimulus.

It does not possess anticholinergic properties.

Pharmacokinetics

After oral administration, it is absorbed from the gastrointestinal tract.

At a dose of 20 mg, C_max is achieved in 3.5 hours.

Changes in C_max and AUC are linear (in the dose range from 10 to 40 mg).

The absolute bioavailability is about 52% due to the first-pass effect through the liver.

The bioavailability of rabeprazole does not increase with repeated administration.

Food intake and time of day do not affect the absorption of rabeprazole.

Plasma protein binding is 97%.

Rabeprazole sodium undergoes a first-pass effect. It is metabolized in the liver with the participation of CYP isoenzymes.

Main metabolites (thioether and carboxylic acid) and minor metabolites (sulfone, dimethyl thioether, and mercapturic acid conjugate) are present in low concentrations.

Indications

Adults aged 18 years and older: gastric ulcer in the acute phase and anastomotic ulcer; duodenal ulcer in the acute phase; erosive GERD or reflux esophagitis, maintenance therapy for GERD, non-erosive GERD; Zollinger-Ellison syndrome and other conditions characterized by pathological hypersecretion; in combination with antibacterial therapy for the eradication of Helicobacter pylori in patients with peptic ulcer disease.

Adolescents aged 12 years and older: GERD.

ICD codes

Dosage Regimen

Administer orally. Swallow the capsule whole with a sufficient amount of water. Do not chew or crush the capsules.

For erosive GERD or reflux esophagitis, take 20 mg once daily for 4 to 8 weeks. For long-term maintenance therapy of GERD, use 10 mg or 20 mg once daily.

For duodenal ulcer, take 20 mg once daily after breakfast for 4 weeks.

For gastric ulcer, take 20 mg once daily for 6 weeks.

For Zollinger-Ellison syndrome, start with 60 mg once daily. Adjust the dose individually; some patients require divided doses. Doses up to 100 mg daily or 60 mg twice daily may be used.

For Helicobacter pylori eradication, use in combination therapy. One common regimen is 20 mg twice daily with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily for 7 days.

For adolescents aged 12 years and older with GERD, the dose is 20 mg once daily for up to 8 weeks.

Take the dose in the morning before a meal. If a dose is missed, take it as soon as remembered. Do not double the dose to make up for a missed one.

For patients with severe hepatic impairment, use with caution; consider a lower starting dose. No dose adjustment is required for patients with renal impairment or mild to moderate hepatic impairment.

Adverse Reactions

Immune system disorders: rarely – acute systemic allergic reactions.

Blood and lymphatic system disorders: rarely – thrombocytopenia, neutropenia, leukopenia.

Metabolism and nutrition disorders: rarely – hypomagnesemia.

Hepatobiliary disorders: infrequently – increased activity of liver enzymes; rarely – hepatitis, jaundice, hepatic encephalopathy.

Renal and urinary disorders: very rarely – interstitial nephritis.

Skin and subcutaneous tissue disorders: rarely – bullous eruptions, urticaria; very rarely – erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome;

Musculoskeletal and connective tissue disorders: rarely – myalgia, arthralgia.

Reproductive system and breast disorders: very rarely – gynecomastia.

Contraindications

Hypersensitivity to rabeprazole or substituted benzimidazoles; pregnancy, breastfeeding period; children under 12 years of age (for all indications), children and adolescents under 18 years of age (except for indications for adolescents over 12 years).

With caution severe renal impairment.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and lactation (breastfeeding).

Use in Hepatic Impairment

No dose adjustment is required for patients with impaired liver function; however, Rabeprazole should be used with caution in patients with severe hepatic impairment.

Use in Renal Impairment

Should be used with caution in patients with severe renal impairment.

Pediatric Use

Contraindicated for use for all indications in children under 12 years of age.

Contraindicated for use in children and adolescents under 18 years of age (except for indications for adolescents over 12 years).

Geriatric Use

Patients aged 55 years and older should consult a doctor if symptoms appear or change during rabeprazole therapy.

Special Precautions

Before starting therapy, it is necessary to exclude malignant neoplasms of the stomach, because the use of rabeprazole may mask symptoms and delay correct diagnosis.

No dose adjustment is required for patients with impaired liver or kidney function; however, Rabeprazole should be used with caution in patients with severe hepatic impairment.

Proton pump inhibitor therapy may lead to an increased risk of gastrointestinal infections caused by Clostridium difficile.

When used concomitantly with rabeprazole, doses of ketoconazole and digoxin should be adjusted.

Patients with long-term recurring symptoms of indigestion or heartburn should be regularly monitored by a doctor.

Patients over 55 years of age who daily take over-the-counter medications to relieve symptoms of heartburn and indigestion should inform their doctor about this.

Rabeprazole should not be used concomitantly with other acid-reducing agents, such as H₂-receptor blockers or proton pump inhibitors.

In experimental studies, no carcinogenic effect of rabeprazole was established; however, ambiguous results were obtained in mutagenicity studies.

Tests on mouse lymphoma cells were positive, while the in vivo micronucleus test and in vivo and in vitro DNA repair tests were negative.

Drug Interactions

With simultaneous use with digoxin, a slight to moderate increase in the plasma concentration of digoxin is possible.

With simultaneous use with ketoconazole, its bioavailability decreases.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.